News

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. The open-label trial will evaluate the safety and clinical effects of NTCELL in patients

Construction has already started and the new Diabetes Research House facility is scheduled to be opened in early 2016. Following completion, the new Diabetes Research House will be

The trial is designed to assess the efficacy and safety of enzalutamide in patients with prostate cancer that has biochemically recurred following definitive local therapy with radical prostatectomy

This commitment from the Gates Foundation also includes additional investments in Affinivax based on the achievement of future success-based milestones. Proceeds from the funding will be used to

ASLAN’s adoption of the industry-leading Medidata Clinical Cloud™ supports the company’s strategy of maximizing the value of its in-licensed drug portfolio by conducting high quality, efficient clinical development

Treatments of other bladder disorders are also covered by the patent, including glycosaminoglycan ("GAG") deficient forms of cystitis or GAG-deficiency, such as, accompanying chronic urinary tract infection, radiation-

US Patent 8,859,530 covers co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis. Formerly known as Voltarra Pharmaceuticals, Levolta’s patent claims methods for treating osteoarthritis by

Ninad Deshpanday, President of R&D at Kemwell said, "With this investment, we are bringing our customers a new service from our US facility. We will offer our clients

XIGDUO XR is a combination of two anti-hyperglycemic agents, dapagliflozin and metformin hydrochloride (HCl) extended-release in a once-daily oral tablet. It is the first and only once-daily combination